Barry Kuang focuses his practice on a wide range of general corporate matters, mergers and acquisitions, venture capital financings, cross border transactions and late-stage transactions.
HealthTrio Combines With mPulse and Decision Point Healthcare Solutions
December 19, 2023
Cooley advised HealthTrio, a top provider of comprehensive health management and member engagement solutions, on its strategic acquisition by mPulse, which also announced its acquisition of Decision Point Healthcare Solutions.
Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.
General Catalyst Leads $100 Million Series B Investment in Modular
August 24, 2023
Cooley advised General Catalyst as lead investor in Modular’s $100 million Series B financing. Modular is a developer of a platform designed to rebuild artificial intelligence infrastructure for everyone. Harley Brown led the Cooley team advising General Catalyst.
General Catalyst Leads $100 Million Series B Investment in Charm Industrial
June 6, 2023
Cooley advised General Catalyst as lead investor in Charm Industrial’s $100 million Series B financing. Charm Industrial is a developer of carbon removal technology, using plants to capture carbon dioxide from the atmosphere, then converting biomass into a stable, carbon-rich liquid to be pumped deep underground. Harley Brown led the Cooley team advising General Catalyst.
CinCor Pharma to Sell to AstraZeneca for Approximately $1.8 Billion
January 10, 2023
Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.
